Clinical Trials
15 trialsNCT05716919 2023-10-23
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Machaon Biotherapeutics, Inc.
Phase 1 Unknown
NCT05690425 2023-07-24
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT05610202 2022-11-09
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05489276 2022-08-05
Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05212584 2022-07-06
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Phase 1 Unknown
NCT05445765 2022-07-06
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Phase 1 Unknown
NCT05020639 2021-09-21
A Study of TQB3820 in Patients With Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04854681 2021-04-22
Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04412577 2021-04-01
A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04397705 2021-02-11
RECAP
The Christie NHS Foundation Trust
Phase 1 Unknown
NCT02503033 2020-09-11
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
Hutchmed
Phase 1 Unknown
NCT04243434 2020-04-16
PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients
Acrotech Biopharma Inc.
Phase 1 Unknown
NCT03110640 2019-11-27
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
First Affiliated Hospital of Wenzhou Medical University
Phase 1 Unknown
NCT02921685 2018-09-19
PIRAT
Institut Paoli-Calmettes
Phase 1 Unknown
NCT03344705 2017-11-17
Safety and Efficacy Evaluation of IM19 Cells
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown